Authors
Médéa Locquet, Jonathan Douxfilx, Patrizio Lancellotti, Jean-Michel Dogné
Published in
Revue medicale de Liege. Volume 81. Issue 11. Pages 632-636.
Abstract
Statins remain central for cardiovascular prevention, but their public health impact also depends on treatment adherence and persistence. The perception of adverse effects, sometimes amplified by poorly contextualized regulatory information, may lead to avoidable treatment discontinuation. A recent meta-analysis by the Cholesterol Treatment Trialists' Collaboration, based on individual participant data from more than 120,000 participants in 19 randomized trials, showed that most non-specific adverse effects commonly attributed to statins were not associated with an excess risk compared with placebo. At the population level, these findings highlight the need to distinguish pharmacovigilance signals from temporal associations and to demonstrate causality. More proportionate risk communication, including absolute frequency, uncertainty and the weight of evidence, may help reduce nocebo effects, support adherence to preventive therapies and preserve the expected cardiovascular benefit. For widely prescribed medicines, the quality of safety information is therefore not only a regulatory issue, but also a direct determinant of public health benefit.
PMID:
43036962
Bibliographic data and abstract were imported from PubMed on 16 Nov 2026.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 1
- Comments 0